Download PDF
Semin Musculoskelet Radiol 2002; 06(3): 207-218
DOI: 10.1055/s-2002-36718
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Dual Energy X-Ray Absorptiometry and Its Clinical Applications

Glen M. Blake, Ignac Fogelman
  • Guy's, King's and St Thomas' School of Medicine, St Thomas Street, London, United Kingdom
Further Information

Publication History

Publication Date:
23 January 2003 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Bone density scans using the technique of dual energy X-ray absorptiometry (DXA) are widely seen as having an essential role in the evaluation of patients at risk of osteoporosis. DXA scans of the spine and hip are the most useful because fractures at these sites result in the greatest impairment of quality of life. A hip DXA scan is the most reliable way of evaluating hip fracture risk, and the spine is the most sensitive site for monitoring response to treatment. Fundamental to the clinical role of DXA scanning are the findings of epidemiological studies that relate fracture risk to bone mineral density. The results of spine and hip DXA scans are interpreted using the World Health Organisation (WHO) definition of osteoporosis as a T-score less than -2.5. DXA scans are also used in longitudinal studies, both for research studies and for follow-up scans of individual patients. Although the former have an important role in the development of new treatments for osteoporosis, the latter are more controversial and are likely to be less important in the future. There is also interest in the use of smaller, less expensive DXA systems for scanning sites in the peripheral skeleton. However, in general, the results from these devices cannot be interpreted using the WHO definition of osteoporosis, and until there is a consensus over establishing an equivalent threshold, their use is premature.

KEYWORD

Bone mineral density - dual energy X-ray absorptiometry - osteoporosis

REFERENCES

  • 1 Genant H K, Engelke K, Fuerst T. Noninvasive assessment of bone mineral and structure: state of the art.  J Bone Miner Res . 1996;  11 707-730
    PubMedGoogle Scholar
  • 2 Baran D T, Faulkner K G, Genant H K. Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry.  Calcif Tissue Int . 1997;  61 433-440
    CrossrefPubMedGoogle Scholar
  • 3 Kanis J A, Delmas P, Burckhardt P, Cooper C, Torgerson D. on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and treatment of osteoporosis.  Osteoporos Int . 1997;  7 390-406
    CrossrefPubMedGoogle Scholar
  • 4 Cooper C, Campion G, Melton L J. Hip fractures in the elderly; a world-wide projection.  Osteoporos Int . 1992;  2 285-289
    CrossrefPubMedGoogle Scholar
  • 5 Schurch M-A, Rizzoli R, Mermillod B. A prospective study on socio-economic aspects of fracture of the proximal femur.  J Bone Miner Res . 1996;  11 1935-1942
    PubMedGoogle Scholar
  • 6 Ray N F, Chan J K, Thamer M, Melton L J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995; report from the National Osteoporosis Foundation.  J Bone Miner Res . 1997;  12 24-35
    PubMedGoogle Scholar
  • 7 Black D M, Cummings S R, Karpf D B. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures.  Lancet . 1996;  348 1535-1541
    CrossrefPubMedGoogle Scholar
  • 8 Ettinger B, Black D M, Mitlak B H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.  JAMA . 1999;  282 637-645
    CrossrefPubMedGoogle Scholar
  • 9 Harris S T, Watts N B, Genant H K. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.  JAMA . 1999;  282 1344-1352
    CrossrefPubMedGoogle Scholar
  • 10 Neer R M, Arnaud C D, Zanchetta J R. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis.  N Engl J Med . 2001;  344 1434-1441
    CrossrefPubMedGoogle Scholar
  • 11 Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis.  Am J Med . 1993;  94 646-650
    CrossrefPubMedGoogle Scholar
  • 12 WHO Technical Report Series 843. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis Geneva: World Health Organization; 1994
  • 13 Heaney R P, Abrams S, Dawson-Hughes B. Peak bone mass.  Osteoporos Int . 2000;  11 985-1009
    PubMedGoogle Scholar
  • 14 Guglielmi G. Quantitative computed tomography.  Semin Musculoskeletal Radiol . 2002;  6 219-228
    PubMedGoogle Scholar
  • 15 Stewart A, Reid D. Quantitative ultrasound in osteoporosis.  Semin Musculoskeletal Radiol . 2002;  6 229-232
    PubMedGoogle Scholar
  • 16 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.  Br Med J . 1996;  312 1254-1259
    CrossrefPubMedGoogle Scholar
  • 17 Cummings S R, Black D M, Nevitt M C. Bone density at various sites for prediction of hip fractures.  Lancet . 1993;  341 72-75
    CrossrefPubMedGoogle Scholar
  • 18 Black D M, Palermo L, Bauer D. How well does bone mass predict long-term risk of hip fracture (Abst)?.  Osteoporos Int. . 2000;  11(Suppl 2) S59
    CrossrefPubMedGoogle Scholar
  • 19 Eastell R. Treatment of postmenopausal osteoporosis.  N Engl J Med . 1998;  338 736-746
    CrossrefPubMedGoogle Scholar
  • 20 Njeh C F, Fuerst T, Hans D, Blake G M, Genant H K. Radiation exposure in bone mineral assessment.  Appl Rad Isotope . 1999;  50 215-236
    PubMedGoogle Scholar
  • 21 Blake G M, Herd R MJ, Patel R, Fogelman I. The effect of weight change on total body dual energy x-ray absorptiometry: results from a clinical trial.  Osteoporos Int . 2000;  11 832-839
    CrossrefPubMedGoogle Scholar
  • 22 Bouxsein M L, Parker R A, Greenspan S L. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.  Osteoporos Int . 1999;  10 505-509
    CrossrefPubMedGoogle Scholar
  • 23 Svendsen O L, Hassager C, Skodt V, Christiansen C. Impact of soft tissue on in-vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study.  J Bone Miner Res . 1995;  10 868-873
    PubMedGoogle Scholar
  • 24 Boudousq V, Kotzki P O, Dinten J M. Radiation dose assessment on patients and staff from a new 2D digital bone densitometer (in press).  Osteoporos Int.
    PubMedGoogle Scholar
  • 25 Cameron J R, Sorensen J A. Measurement of bone mineral in vivo: an improved method.  Science . 1963;  142 230-232
    PubMedGoogle Scholar
  • 26 Düppe H, Gärdsell P, Nilsson B, Johnell O. A single bone density measurement can predict fractures over 25 years.  Calcif Tissue Int . 1997;  60 171-174
    CrossrefPubMedGoogle Scholar
  • 27 Patel R, Blake G M, Fogelman I. Radiation dose to the patient and operator from a peripheral dual x-ray absorptiometry system.  J Clin Densitom . 1999;  2 397-401
    PubMedGoogle Scholar
  • 28 Faulkner K G, VonStetton E, Miller P. Discordance in patient classification using T-scores.  J Clin Densitom . 1999;  2 343-350
    CrossrefPubMedGoogle Scholar
  • 29 Black D M. Revision of T-score BMD diagnostic thresholds (Abst).  Osteoporosis Int . 2000;  11(Suppl 2) S58
    PubMedGoogle Scholar
  • 30 Blake G M, Knapp K M, Fogelman I. Absolute fracture risk varies with bone densitometry technique used: a theoretical and in-vivo study of fracture cases.  J Clin Densitom . 2002;  5 109-116
    CrossrefPubMedGoogle Scholar
  • 31 Liberman U A, Weiss S R, Bröll J. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.  N Engl J Med . 1995;  333 1437-1443
    CrossrefPubMedGoogle Scholar
  • 32 Tonino R P, Meunier P J, Emkey R. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women.  J Clin Endocrinol Metab . 2000;  85 3109-3115
    CrossrefPubMedGoogle Scholar
  • 33 Cummings S R, Black D M, Thompson D E. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial.  JAMA . 1998;  280 2077-2082
    CrossrefPubMedGoogle Scholar
  • 34 Reginster J-Y, Minne H W, Sorensen O H. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.  Osteoporos Int . 2000;  11 83-91
    CrossrefPubMedGoogle Scholar
  • 35 Chesnut C H, Silverman S, Andriano K. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study.  Am J Med . 2000;  109 267-276
    CrossrefPubMedGoogle Scholar
  • 36 McClung M R, Geusens P, Miller P D. Effect of risedronate treatment on hip fracture risk in elderly women.  N Engl J Med . 2001;  344 333-340
    CrossrefPubMedGoogle Scholar
  • 37 Reid I R, Brown J P, Burckhardt P. Intravenous zolendronic acid in postmenopausal women with low bone mineral density.  N Engl J Med . 2002;  346 653-661
    CrossrefPubMedGoogle Scholar
  • 38 Cummings S R, Palermo L, Browner W. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean.  JAMA . 2000;  283 1318-1321
    CrossrefPubMedGoogle Scholar
  • 39 Blake G M, Fogelman I. Peripheral or central densitometry: does it matter which technique we use?.  J Clin Densitom . 2001;  4 83-96
    CrossrefPubMedGoogle Scholar
  • 40 Altman D G. Practical Statistics for Medical Research.  London: Chapman Hall; 1991
    Google Scholar
  • 41 Cummings S R, Black D M, Nevitt M C. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group.  JAMA . 1990;  263 665-668
    CrossrefPubMedGoogle Scholar
  • 42 Seeley D G, Browner W S, Nevitt M C. Which fractures are associated with low appendicular bone mass in elderly women?.  Ann Intern Med . 1991;  115 837-842
    PubMedGoogle Scholar
  • 43 Siris E S, Miller P D, Barrett-Connor M D. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.  JAMA . 2001;  286 2815-2822
    CrossrefPubMedGoogle Scholar
  • 44 Faulkner K, Abbott T A, Furman W D. Fracture risk assessment in NORA is comparable across peripheral sites (Abst).  J Bone Miner Res . 2000;  15(Suppl 1) S144
    PubMedGoogle Scholar
  • 45 Faulkner K G, Roberts L A, McClung M R. Discrepancies in normative data between Lunar and Hologic DXA systems.  Osteoporos Int . 1996;  6 432-436
    CrossrefPubMedGoogle Scholar
  • 46 Hanson J. Standardization of femur BMD (Letter).  J Bone Miner Res . 1997;  12 1316-1317.
    PubMedGoogle Scholar
  • 47 Looker A C, Wahner H W, Dunn W L. Updated data on proximal femur bone mineral levels of US adults.  Osteoporos Int . 1998;  8 468-489
    CrossrefPubMedGoogle Scholar
  • 48 Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip reference values affect the densitometric diagnosis of osteoporosis.  Osteoporos Int . 1998;  8 423-427
    CrossrefPubMedGoogle Scholar
  • 49 Genant H K, Grampp S, Glüer C-C. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results.  J Bone Miner Res . 1994;  9 1503-1514
    PubMedGoogle Scholar
  • 50 Steiger P. Standardization of spine BMD (Letter).  J Bone Miner Res . 1995;  10 1602-1603
    PubMedGoogle Scholar
  • 51 National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis.  Osteoporos Int . 1998;  8(Suppl 4) S7-S80
    PubMedGoogle Scholar
  • 52 Royal College of Physicians. Osteoporosis: Clinical Guidelines for Prevention and Treatment London: Royal College of Physicians; 1999
  • 53 National Osteoporosis Foundation. Physicians Guide to Prevention and Treatment of Osteoporosis Washington, DC: National Osteoporosis Foundation; 1998
  • 54 Royal College of Physicians. Osteoporosis: Clinical Guidelines for Prevention and Treatment. Update on Pharmacological Interventions and an Algorithm for Management. London: Royal College of Physicians; 2000
  • 55 Kanis J A, Glüer C-C. An update on the diagnosis and assessment of osteoporosis with densitometry.  Osteoporos Int . 2000;  11 192-202
    CrossrefPubMedGoogle Scholar
  • 56 Glüer C-C, Blake G, Lu Y. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques.  Osteoporos Int . 1995;  5 262-270
    CrossrefPubMedGoogle Scholar
  • 57 Patel R, Blake G M, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women.  Osteoporos Int . 2000;  11 68-75
    CrossrefPubMedGoogle Scholar
  • 58 Hoskings D, Chilvers C E, Christiansen C. Prevention of bone loss in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group.  N Engl J Med . 1998;  338 485-492
    CrossrefPubMedGoogle Scholar
  • 59 Faulkner K G. Bone densitometry: choosing the proper skeletal site to measure.  J Clin Densitom . 1998;  1 279-285
    CrossrefPubMedGoogle Scholar
  • 60 Blake G M, Herd R JM, Fogelman I. A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total body DXA.  Osteoporos Int . 1996;  6 462-470
    CrossrefPubMedGoogle Scholar